Mark Kirschbaum - Jun 30, 2023 Form 4 Insider Report for Cyclacel Pharmaceuticals, Inc. (CYCC)

Role
Chief Medical Officer
Signature
/s/ Mark Kirschbaum
Stock symbol
CYCC
Transactions as of
Jun 30, 2023
Transactions value $
$0
Form type
4
Date filed
7/3/2023, 04:56 PM
Previous filing
Feb 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYCC Stock Option (right to buy) Award $0 +70.2K $0.00 70.2K Jun 30, 2023 Common Stock 70.2K $0.59 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person received an award of 70,200 options on June 30, 2023, which shall vest in full on June 30, 2026, provided, however, that if certain clinical milestones are achieved then such options shall vest in full earlier in connection with such achievement.